B
TNYA icon

Bailard’s Tenaya Therapeutics TNYA Stock Holding History

Bailard’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-32,900
Closed -$102K – 818
2024
Q2 		$102K Hold
32,900
– – ﹤0.01% 714
2024
Q1 		$172K Hold
32,900
– – ﹤0.01% 705
2023
Q4 		$107K Buy
+32,900
New +$71K ﹤0.01% 688

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Bailard's TNYA Position: Q3 2024 in Review

Bailard sold out of Tenaya Therapeutics (TNYA) in Q3 2024, closing a stake of 32,900 shares — an estimated $102K sold.

Bailard first reported a position in TNYA in Q4 2023 and held it in 3 quarters. The position peaked at $172K in Q1 2024. 95 funds tracked by Wall St. Rank hold TNYA as of Q3 2024.

  • Bailard reported no remaining Tenaya Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bailard sold 32,900 Tenaya Therapeutics shares in Q3 2024, an estimated $102K.
  • Bailard first reported a position in Tenaya Therapeutics in Q4 2023 and held it in 3 quarters.
  • Bailard's Tenaya Therapeutics position peaked at $172K in Q1 2024.
  • 95 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q3 2024.

Based on Bailard's 13F filing for Q3 2024, filed 30 Oct 2024.